Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2010 Jul 7;2010(7):CD005415.
doi: 10.1002/14651858.CD005415.pub3.

Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding

Aravamuthan Sreedharan  1 , Janet Martin, Grigorios I Leontiadis, Stephanie Dorward, Colin W Howden, David Forman, Paul Moayyedi
Affiliations
Meta-Analysis

Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding

Aravamuthan Sreedharan et al. Cochrane Database Syst Rev. .

Update in

Abstract

Background: There is conflicting evidence regarding the clinical efficacy of proton pump inhibitors (PPI) initiated before endoscopy for upper gastrointestinal bleeding.

Objectives: To systematically review evidence from randomised controlled trials (RCTs) of PPI treatment initiated before endoscopy for upper gastrointestinal bleeding.

Search strategy: We searched CENTRAL (The Cochrane Library), MEDLINE, EMBASE and CINAHL databases and major conference proceedings to September 2005, using the Cochrane Upper Gastrointestinal and Pancreatic Diseases model. Searches were re-run in February 2006 and October 2008.

Selection criteria: We selected randomised controlled trials (RCTs), of hospitalised participants with unselected upper gastrointestinal bleeding, undergoing active treatment with a proton pump inhibitor PPI (oral or intravenous) and control treatment with either placebo, histamine-2 receptor antagonist (H2RA) or no treatment prior to endoscopy. Outcomes were assessed at 30 days and included mortality, rebleeding and surgery. Also assessed were stigmata of recent haemorrhage (SRH; active bleeding, non bleeding visible vessel or adherent clot) at index endoscopy, length of hospital stay, blood transfusion requirements and requirement for endoscopic therapy at index endoscopy.

Data collection and analysis: At least two review authors assessed eligibility criteria and extracted data regarding outcomes and factors affecting methodological quality.

Main results: Six RCTs comprising 2223 participants were included. There was no statistical heterogeneity among trials for dichotomous outcomes. There were no statistically significant differences in mortality, rebleeding or surgery between PPI and control treatment. Unweighted pooled mortality rates were 6.1% and 5.5% respectively (odds ratio (OR)1.12; 95% CI 0.72 to 1.73). Unweighted pooled rebleeding rates were 13.9% and 16.6% respectively (OR 0.81; 95%CI 0.61 to 1.09). Pooled rates for surgery were 9.9% and 10.2% respectively (OR 0.96 95% CI 0.68 to 1.35). PPI treatment compared to control significantly reduced the proportion of participants with SRH at index endoscopy; unweighted pooled rates were 37.2% and 46.5% respectively (OR 0.67; 95% CI 0.54 to 0.84). However, this result was not robust to sensitivity analysis. PPI treatment compared to control significantly reduced endoscopic therapy at index endoscopy; unweighted pooled rates were 8.6% and 11.7% respectively (OR 0.68; 95% CI 0.50 to 0.93). For continuous outcomes (length of hospital stay and blood transfusion requirements), quantitative analysis could not be performed.

Authors' conclusions: PPI treatment initiated before endoscopy for upper gastrointestinal bleeding might reduce the proportion of participants with SRH at index endoscopy and significantly reduces requirement for endoscopic therapy during index endoscopy. However, there is no evidence that PPI treatment affects clinically important outcomes, namely mortality, rebleeding or need for surgery.

PubMed Disclaimer

Conflict of interest statement

A Sreedharan ‐ Has received speaker fees from Astra Zeneca and has accepted honoraria from Abbott for attending scientific meetings

Janet Martin ‐ co‐investigator in a partner grant between industry (Astra Zeneca) and CIHR, but does not receive any payment from this grant.

G Leontiadis ‐ Has received speaker fees and reimbursement for expenses to attend scientific meetings from AstraZeneca, Sanofi‐Aventis, Janssen‐Cilag and GlaxoSmithKline.

D Forman ‐ Has received speaker fees from Astra Zeneca

P Moayyedi ‐ Chair is partly funded by an unrestricted donation from AstraZeneca to McMaster University.

Has been on the speaker's bureau for AstraZeneca, Altana and Janssen‐Ortho

Has been on the advisory boards of AstraZeneca and Janssen‐Ortho

C Howden ‐ Previously consulted for TAP Pharmaceutical Products Inc, Takeda Chemical Industries, and Altana Pharma

Currently consults for Santarus Inc., Takeda Pharmaceuticals North America, Procter & Gamble, Xenoport

Speaker's bureau for Santarus Inc, AstraZeneca and Takeda Pharmaceuticals North America

Previous research grant support from AstraZeneca

Was previously an investigator and speaker for Merck.

Figures

1
1
Funnel plot of comparison: 1 Main analysis, outcome: 1.1 Mortality ‐ 30 days or at point closest to 30 days.
2
2
Funnel plot of comparison: 1 Main analysis, outcome: 1.2 Rebleeding within 30 days.
3
3
Funnel plot of comparison: 1 Main analysis, outcome: 1.3 Surgery for continued or recurrent bleeding within 30 days of randomisation.
4
4
Funnel plot of comparison: 1 Main analysis, outcome: 1.5 Proportion of patients with stigmata of recent haemorrhage.
5
5
Funnel plot of comparison: 1 Main analysis, outcome: 1.8 Endoscopic haemostatic therapy at index endoscopy.
1.1
1.1. Analysis
Comparison 1 Main analysis, Outcome 1 Mortality ‐ 30 days or at point closest to 30 days.
1.2
1.2. Analysis
Comparison 1 Main analysis, Outcome 2 Rebleeding within 30 days.
1.3
1.3. Analysis
Comparison 1 Main analysis, Outcome 3 Surgery for continued or recurrent bleeding within 30 days of randomisation.
1.4
1.4. Analysis
Comparison 1 Main analysis, Outcome 4 Patients requiring blood transfusion (post hoc analysis).
1.5
1.5. Analysis
Comparison 1 Main analysis, Outcome 5 Proportion of patients with stigmata of recent haemorrhage.
1.6
1.6. Analysis
Comparison 1 Main analysis, Outcome 6 Proportion of patients with blood in stomach (post hoc analysis).
1.7
1.7. Analysis
Comparison 1 Main analysis, Outcome 7 Proportion of patients with active bleeding.
1.8
1.8. Analysis
Comparison 1 Main analysis, Outcome 8 Endoscopic haemostatic therapy at index endoscopy.
2.1
2.1. Analysis
Comparison 2 Analysis according to degree of allocation concealment, Outcome 1 Mortality.
2.2
2.2. Analysis
Comparison 2 Analysis according to degree of allocation concealment, Outcome 2 Rebleeding within 30 days.
2.3
2.3. Analysis
Comparison 2 Analysis according to degree of allocation concealment, Outcome 3 Surgery for continued or recurrent bleeding within 30 days of randomisation.
3.1
3.1. Analysis
Comparison 3 Analysis according to control treatment, Outcome 1 Mortality.
3.2
3.2. Analysis
Comparison 3 Analysis according to control treatment, Outcome 2 Rebleeding within 30 days.
3.3
3.3. Analysis
Comparison 3 Analysis according to control treatment, Outcome 3 Surgery for continued or recurrent bleeding within 30 days of randomisation.
4.1
4.1. Analysis
Comparison 4 Analysis according to route of PPI administration, Outcome 1 Mortality.
4.2
4.2. Analysis
Comparison 4 Analysis according to route of PPI administration, Outcome 2 Rebleeding within 30 days.
4.3
4.3. Analysis
Comparison 4 Analysis according to route of PPI administration, Outcome 3 Surgery for continued or recurrent bleeding within 30 days of randomisation.
5.1
5.1. Analysis
Comparison 5 Analysis according to the PPI used, Outcome 1 Mortality.
5.2
5.2. Analysis
Comparison 5 Analysis according to the PPI used, Outcome 2 Rebleeding within 30 days.
5.3
5.3. Analysis
Comparison 5 Analysis according to the PPI used, Outcome 3 Surgery for continued or recurrent bleeding within 30 days of randomisation.
6.1
6.1. Analysis
Comparison 6 Analysis according to report of endoscopic haemostatic treatment, Outcome 1 Mortality.
6.2
6.2. Analysis
Comparison 6 Analysis according to report of endoscopic haemostatic treatment, Outcome 2 Rebleeding.
6.3
6.3. Analysis
Comparison 6 Analysis according to report of endoscopic haemostatic treatment, Outcome 3 Surgery.
7.1
7.1. Analysis
Comparison 7 Analysis restricted to peptic ulcer patients, Outcome 1 Mortality.
7.2
7.2. Analysis
Comparison 7 Analysis restricted to peptic ulcer patients, Outcome 2 Rebleeding.
7.3
7.3. Analysis
Comparison 7 Analysis restricted to peptic ulcer patients, Outcome 3 Surgery.
See this image and copyright information in PMC

Update of

Comment in

References

References to studies included in this review

Daneshmend 1992 {published data only}
    1. Daneshmand TK, Hawkey CJ, Langman MJ, Logan RG, Walt RP. Omeprazole versus placebo for acute upper gastrointestinal bleeding: Randomised double blind controlled trial. BMJ 1992;304:143‐7. - PMC - PubMed
Hawkey 2001 {published data only}
    1. Hawkey GM, Cole AT, McIntyre AS, Long RG, Hawkey CJ. Drug Treatments in upper gastrointestinal bleeding: value of endoscopic findings as surrogate end points. Gut 2001;49:372‐9. - PMC - PubMed
Hulagu 1995 {published data only}
    1. Hulagu S, Demirturk L, Gul S, Yazgan Y, Altin M, Danaci M. The effect of omeprazole or ranitidine intravenous on upper gastrointestinal bleeding. Endoskopi Journal 1995;2:35‐43.
Lau 2007 {published data only (unpublished sought but not used)}
    1. Lau JY, Leung WK, Wu JCY, Chan FKL, Wong VWS, Chiu PWY, et al. Omeprazole before endoscopy in patients with gastrointestinal bleeding. The New England Journal of Medicine 2007;356:1631‐40. - PubMed
Naumovski 2005 {published data only}
    1. Naumovski‐Mihalic S, Katicic M, Colic‐Cvlje V, Bozek T, Prskalo M, Sabaric B, et al. Intravenous proton pump inhibitor in ulcer bleeding in patients admitted to an intensive care unit. Gastroenterology 2005;128 suppl 4:W1578.
Wallner 1996 {published data only}
    1. Wallner G, Ciechanski A, Wesolowski M, Sory A, Misiuna P. Treatment of acute upper gastrointestinal bleeding with intravenous omeprazole or ranitidine. European Journal of Clinical Research 1996;8:235‐43.

References to studies excluded from this review

Al‐Sabah 2008 {published data only}
    1. Al‐Sabah S, Barkun AN, Herba K, Adam V, Fallone C, Mayrand S, et al. Cost‐effectiveness of proton‐pump inhibition before endoscopy in upper gastrointestinal bleeding. Gastroenterology 2008;135(5):1790‐2. - PubMed
Andrews 2005 {published data only}
    1. Andrews CN, Levy A, Fishman M, Hahn M, Atkinson K, Kwan P, et al. Intravenous proton pump inhibitors before endoscopy in bleeding peptic ulcer with high risk stigmata: a multicentre comparative study. Canadian Journal of Gastroenterology 2005;19(11):667‐71. - PubMed
Avgerinos 2005 {published data only}
    1. Avgerinos A, Sgouros S, Viazis N, Vlachogiannakos J, Papaxoinis K, Bergele C, et al. Somatostatin inhibits gastric acid secretion more effectively than pantoprazole in patients with peptic ulcer bleeding: A prospective randomized placebo controlled trial. Scandinavian Journal of Gastroenterology 2005;40(5):515‐22. - PubMed
Bai 1995 {published data only}
    1. Bai G, Hu FL, Lu DH, Qin J. Efficacy of intravenous administration of omeprazole in the treatment of upper gastrointestinal haemorrhage caused by peptic ulcer and acute gastric mucosal lesion. The Chinese Journal of Clinical Pharmacology 1995;11:206‐9.
Bajaj 2007 {published data only}
    1. Bajaj JS, Dua KS, Hanson K, Presberg K. Prospective randomized trial comparing effect of oral versus intravenous pantoprazole on rebleeding after nonvariceal upper gastrointestinal bleeding: A pilot study. Digestive Diseases & Sciences 2007;52(9):2190‐4. - PubMed
Brunner 1990 {published data only}
    1. Brunner G, Chang J. Intravenous therapy with high doses of ranitidine and omeprazole in critically ill patients with bleeding peptic ulcerations of the upper intestinal tract: An open randomised controlled trial. Digestion 1990;45(4):217‐25. - PubMed
Cheng 2005 {published data only}
    1. Cheng HC, Kao AW, Chuang CH, Sheu BS. The efficacy of high and low dose intravenous omeprazole in preventing rebleeding for patients with bleeding peptic ulcers and comorbid illnesses. Digestive Diseases and Sciences 2005;50(7):1194‐1201. - PubMed
Chu 1993 {published data only}
    1. Chu XQ, Jia LS. Effects of omeprazole and ranitidine on the treatment of peptic ulcer hemorrhage. Journal of Gastroenterology and Hepatology 1993;8(Suppl 2):S239.
Colin 1993 {published data only}
    1. Colin R, Michel P, Sallerin V. Comparison of the efficacy of lansoprazole and ranitidine in the prevention of early relapse in people with upper gastrointestinal ulcerative haemorrhage with a high risk of early recurrence of rebleeding. A double blind multi centre study. Gastroenterolgie Clinique et Biologique 1993;17:A105.
Costamagna 1998 {published data only}
    1. Costamagna G, Mutignani M, Perri V, Colombo GM, Bruni A, Gabbrielli A, D Pietro C, Cruciiti F. Lansoprazole in preventing bleeding relapse in upper gastrointestinal non variceal bleeding. Gatroenterology 1998;114(Suppl.):A95.
Dovas 1992 {published data only}
    1. Dovas A. Medical treatment of active bleeding of upper gastrointestinal tract: Omeprazole or H2 antagonists? A comparative study. Annales Medicales 1992:169‐72.
Elphick 2007 {published data only}
    1. Elphick DA, Riley SA. Omeprazole before endoscopy in patients with gastrointestinal bleeding. New England Journal of Medicine 2007; Vol. 357:303. - PubMed
Fasseas 2001 {published data only}
    1. Fasseas P, Leybishkis B, Rocca G. Omeprazole versus ranitidine in the medical treatment of acute upper gastrointestinal bleeding: assessment by repeat early endoscopy. International Journal of Clinical Practice 2001;55:661‐4. - PubMed
Felder 1998 {published data only}
    1. Felder LR, Barkin JS. A comparison of omeprazole and placebo for bleeding peptic ulcer. Gastrointestinal Endoscopy 1998;47(5):428‐9. - PubMed
Fried 1999 {published data only}
    1. Fried R, Beglinger C, Meier R, Stumpf J, Adler G, Schepp W, et al. Comparison on intravenous Pantoprazole with intravenous ranitidine in peptic ulcer bleeding. Gut 1999;45(Suppl V):A100.
Gao 1995 {published data only}
    1. Gao Z, Deng C, Yi J. The effect of omeprazole on upper gastrointestinal haemorrhage. Acta Academaie Medicinae Hubei 1995;16:223‐5.
Goletti 1994 {published data only}
    1. Goletti O, Sidoti F, Lippolis PV, Negri F, Cavina E. Omeprazole versus ranitidine plus somatostatin in the treatment of severe gastroduodenal bleeding: A prospective, randomised controlled trial. Italian Journal of Gastroenterology 1994;26:72‐4. - PubMed
Hasselgren 1998 {published data only}
    1. Hasselgren G. Optimisation of acid suppression for patients with peptic ulcer bleeding. An intra gastric pH‐metry study with omeprazole. European Journal of Gastroenterology and Hepatology 1998;10:601‐6. - PubMed
Hulagu 1994 {published data only}
    1. Hulagu S, Demirturk L, Gul S, Yazgan Y, Altin M, Danaci M. The effect of omeprazole or ranitidine intravenous on upper gastrointestinal bleeding. Endoscopy 1994;26:404.
Hung 2007 {published data only}
    1. Hung WK, Li VKM, Chung CK, Ying MW, Loo CK, Liu CKT, et al. Randomized trial comparing pantoprazole infusion, bolus and no treatment on gastric PH and recurrent bleeding in peptic ulcers. Australian and New Zealand Journal of Surgery 2007;77(8):677‐81. - PubMed
Jensen 2006 {published data only}
    1. Jensen DM, Pace SC, Soffer E, Comer GM. Continuous infusion of pantoprazole versus ranitidine for prevention of ulcer rebleeding: A US multicenter randomized double‐blind study. American Journal of Gastroenterology 2006;101(9):1991‐99. - PubMed
Keyvani 2006 {published data only}
    1. Keyvani L, Murthy S, Leeson S, Targownik LE. Pre‐endoscopic proton pump inhibitor therapy reduces recurrent adverse gastrointestinal outcomes in patients with acute non‐variceal upper gastrointestinal bleeding. Alimentary Pharmacology and Therapeutics 2006;24(8):1247‐55. - PubMed
Kim 2007 {published data only}
    1. Kim JI, Cheung DY, Cho SH, Park SH, Han JY, Kim JK, et al. Oral proton pump inhibitors are as effective as endoscopic treatment for bleeding peptic ulcer: a prospective, randomized controlled trial. Digestive Diseases & Sciences 2007;52(12):3371‐6. - PubMed
Lau 2005 {published data only}
    1. Lau JY, Leung WK, Wu JC, Chan FK, Wong V, Hung LC, et al. Early administration of high dose intravenous omeprazole prior to endoscopy in patients with upper gastrointestinal bleeding: A double blind placebo controlled randomized trial. Gastroenterology. 2005; Vol. 128 (suppl 4), issue Suppl 4:A 347.
Lee 2003 {published data only}
    1. Lee KK, You JH, Wong IC. Cost‐effectiveness analysis of high‐dose omeprazole infusion as adjuvant therapy to endoscopic treatment of bleeding peptic ulcer. Gastrointestinal Endoscopy 2003;57:160‐4. - PubMed
Lin 2007 {published data only}
    1. Lin HJ. Pre‐endoscopic PPI therapy reduces recurrent adverse outcomes in acute non‐variceal upper gastrointestinal bleeding [comment]. Aliment Pharmacol Ther 2007;25(3):343‐4. - PubMed
Liu 2002 {published data only}
    1. Liu RH, Wei CM, Wang XP, Yin ZZ. The efficacy of Losec versus famotidine in the treatment of bleeding duodenal ulcer. Shanghai Medical and Pharmaceutical Journal 2002;23(7):199‐201.
Maculotti 1995 {published data only}
    1. Maculotti L, Pradella P. Comparison between ranitidine, famotidine and omeprazole in the treatment of bleeding duodenal ulcer. Minerva Chirurgica 1995;50(3):279‐81. - PubMed
Munkel 1997 {published data only}
    1. Munkel L, French L. Treatment of bleeding peptic ulcers with omeprazole. Journal of Family Practice 1997;45(1):20‐1. - PubMed
Murthy 2007 {published data only}
    1. Murthy S, Keyvani L, Leeson S, Targownik LE. Intravenous versus high‐dose oral proton pump inhibitor therapy after endoscopic haemostasis of high risk lesions in patients with acute nonvariceal upper gastrointestinal bleeding. Digestive Diseases & Sciences 2007;52(7):1685‐90. - PubMed
Nehme 2001 {published data only}
    1. Nehme O, Barkin JS. Recurrent ulcer bleeding: Is intravenous omeprazole the solution. American journal of Gastroenterology 2001;96(2):594‐5. - PubMed
Orti 1995 {published data only}
    1. Orti E, Canelles P, Quiles F, Zapater R, Cuquerella J, Ariete V, et al. Is upper gastrointestinal bleeding evolution influenced by the used antisecretory. Revista Espanola De Enfermedades Digestivas 1995;87:427‐30. - PubMed
Perez Flores 1994 {published data only}
    1. Perez Flores R, Garcia Molinero MJ, Herrero Quiros C, Blasco Colmenarejo MM, Caneiro Alcubilla E, Garcia‐Rayo Somoza M, et al. The treatment of upper digestive hemorrhage of peptic origin: intravenous ranitidine versus intravenous omeprazole. Revista Española de Enfermedades Digestivas 1994;86(3):637‐41. - PubMed
Savides 2001 {published data only}
    1. Savides TJ, Pratha V. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. Gastrointestinal Endoscopy 2001;54(1):130‐2. - PubMed
Schaffalitzky 2007 {published data only}
    1. Schaffalitzky de Muckadell OB. Acid pump inhibitor before gastroscopy for upper gastrointestinal bleeding. Ugeskrift for Læger 2007;169(35):2903. - PubMed
Scheurlen 2000 {published data only}
    1. Scheurlen M. Peptic ulcer hemorrhage: IV antacid prevents recurrence. Fortschritte der Medzin 2000;142(45):30. - PubMed
Schonekas 1999 {published data only}
    1. Schonekas H, Ahrens H, Pannewick U, Ell C, Koop H, Petritsch W, et al. Comparison of two doses of intravenous pantoprazole in peptic ulcer bleeding. Gut 1999;45(Suppl V):A104.
Srinath 1997 {published data only}
    1. Srinath C. Comparison of omeprazole and placebo for bleeding peptic ulcer. Tropical Gastroenterology 1997;18(3):115‐6. - PubMed
Sung 2003 {published data only}
    1. Sung JY, Chan FK, Lau JWW. The effect of endoscopic therapy in patients receiving omeprazole for bleeding ulcers with non bleeding visible vessels or adherent clots: A randomised comparison. Annals of Internal Medicine 2003;139:237‐43. - PubMed
Sung 2008 {published data only}
    1. Sung JJY, Mossner J, Barkun A, Kuipers EJ, Lau J, Jensen D, et al. Intravenous esomeprazole for prevention of peptic ulcer re‐bleeding: Rationale/design of peptic ulcer bleed study. Alimentary Pharmacology and Therapeutics 2008;27(8):666‐7. - PubMed
Tran 2007 {published data only}
    1. Tran HA, Kang E, Becker D. Omeprazole before endoscopy in patients with gastrointestinal bleeding [comment]. New England Journal of Medicine 2007;357(3):303‐304. - PubMed
Tsoi 2008 {published data only}
    1. Tsoi KKF, Lau JYW, Sung JJY. Cost‐effectiveness analysis of high‐dose omeprazole infusion before endoscopy for patients with upper‐GI bleeding. Gastrointestinal endoscopy 2008;67:1056‐63. - PubMed
Udd 2001 {published data only}
    1. Udd M, Miettinen P, Janatuinen E, Heikkinen M, Tarvainen R, Pasanen P, et al. Regular versus high dose omeprazole for peptic ulcer bleeding ‐ prospective randomised double blind study. Annales Chirurgiae et Gynaecologiae 1999;88(2):169.
Uribarrena 1994 {published data only}
    1. Uribarrena R, Bajador E, Simon MA, Sebastian JJ, Gomollon F. Omeprazole and cimetidine in the treatment of upper digestive haemorrhage. Revista Espanola de Enfermedades Digestivas 1994;86:878‐83. - PubMed
Wei 2007 {published data only}
    1. Wei KL, Tung SY, Sheen CH, Chang TS, Lee IL, Wu CS. Effect of oral esomeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. Journal of Gastroenterology and Hepatology 2007;22(1):43‐6. - PubMed
Wu 2001 {published data only}
    1. Wu N, Wang SJ, Wang SG, Pan GH. Therapeutic efficacy of pantoprazole on upper gastrointestinal hemorrhage. Chinese New Medicine 2001;2(12):1091‐2.
Xuan 2003 {published data only}
    1. Xuan JL. Loseco compared with famotisine in the treatment of upper gastrointestinal bleeding: clinical analysis of 90 cases. Guangxi Medical Journal 2003;25:529‐31.
Yilmaz 2006 {published data only}
    1. Yilmaz S, Bayan K, Tuzun Y, Dursun M, Canoruc F. A head to head comparison of oral vs intravenous omeprazole for patients with bleeding peptic ulcers with a clean base, flat spots and adherent clots. World Journal of Gastroenterology. 2006;12(48):7837‐43. - PMC - PubMed
Zargar 2006 {published data only}
    1. Zargar SA, Javid G, Khan BA, Yattoo GN, Shah AH, Gulzar GM, et al. Pantoprazole infusion as adjuvant therapy to endoscopic treatment in patients with peptic ulcer bleeding: Prospective randomized controlled trial. Journal of Gastroenterology and Hepatology 2006;21(4):716‐21. - PubMed

Additional references

Andrews 2002
    1. Andrews C, Zandieh I, Brodie M. Appropriateness of discontinuation of intravenous proton pump inhibitor (IV PPI) in bleeding peptic ulcer patients without high risk ulcer stigmata at endoscopy: preliminary results of multicenter evaluation. Gastrointestinal Endoscopy 2002;55(5):A592.
Andrews 2002a
    1. Andrews C, Zandieh I, Levy AR. Comparison of intravenous proton pump inhibitor (IV PPI) use between hospitals:preliminary results. Gastrointestinal Endoscopy 2002;55(5):T1874.
Andriulli 2005
    1. Andriulli A, Annese V, Caruso N, Pilotto A, Accadia L, Niro AG, Quitadamo M, Merla A, Fiorella S, Leandro G. Proton‐pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: a series of meta‐analyses. American Journal of Gastroenterology 2005;100(9):2133. - PubMed
Bardou 2005
    1. Bardou M, Toubouti Y. Benhaberou‐Brun D, Rahme E, Barkun AN. Meta‐analysis: proton‐pump inhibition in high‐risk patients with acute peptic ulcer bleeding. Alimentary Pharmacology and Therapeutics 2005;21:677‐86. - PubMed
Barkun 2003
    1. Barkun AN, Bardou M, Marshall JK. Consensus Recommendations for Managing Patients with Nonvariceal Upper Gastrointestinal Bleeding Conference Group. Annals of Internal Medicine 2003;169:843‐57. - PubMed
Barkun 2004
    1. Barkun A N, Herba K, Adam V, Kenedy W, Fallone C A, Bardou M. High dose intravenous proton pump inhibition following endoscopic therapy in the acute management of patients with bleeding peptic ulcer in the USA and Canada : A Cost‐effective analysis. Alimentary Pharmacology and Therapeutics 2004;19:591‐600. - PubMed
Barkun 2006
    1. Barkun A, Bardou M. The role of PPI therapy in upper GI tract bleeding. Gastroenterology and Hepatology Annual Review 2006; Vol. 1:20‐4.
Barkun 2010
    1. Barkun A, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, Sinclair P, for the International Consensus Upper Gastrointestinal Bleeding Conference Group. International consensus recommendations on the management of patients with non‐variceal upper gastrointestinal bleeding (ICON‐UGIB). Annals of Internal Medicine 2010 (in press). - PubMed
Blatchford 1997
    1. Blatchford O, Davidson LA, Murray WR, Blatchford M, Pell J. Acute upper gastrointestinal haemorrhage in west of Scotland: A case ascertainment study. BMJ 1997;315:510‐4. - PMC - PubMed
Brunner 1996
    1. Brunner G, Luna P, Hartman M, Wurst W. Optimising the intra gastric PH as supportive therapy in upper GI bleeding. Yale J Biol Med 1996;69:225‐31. - PMC - PubMed
Cook 1992
    1. Cook DJ, Guyatt GH, Salena BJ, Laine LA. Endoscopic therapy for acute nonvariceal upper gastrointestinal hemorrhage:a meta‐analysis. Gastroenterology 1992;102:139‐48. - PubMed
Enns 2003
    1. Enns RA, Gagnon YM, Rioux KP, Levy AR. Cost‐effectiveness in Canada of intravenous proton pump inhibitors for all patients presenting with acute upper gastrointestinal bleeding. Alimentary Pharmacology and Therapeutics 2003;17:225‐233. - PubMed
Gagnon 2003
    1. Gagnon YM, Levy AR, Eloubeidi MA. Cost implications of administering intravenous proton pump inhibitors to all patients presenting to the emergency department with peptic ulcer bleeding. Value Health 2003;6:457‐65. - PubMed
Gilbert 1990
    1. Gilbert DA. Epidemiology of upper gastrointestinal bleeding. Gastrointestinal Endoscopy 1990;36:S8‐13. - PubMed
Gisbert 2001
    1. Gisbert JP, Gonzalez L, Calvet X, Roque M, Gabriel R, Pajares JM. Proton pump inhibitors versus H2‐antagonists: a meta‐analysis of their efficacy in treating bleeding peptic ulcer. Alimentaryt Pharmacology and Therapeutics. 2001;15(7):917‐26. - PubMed
Gralnek 1997
    1. Gralnek IM, Jensen DM, Kovacs TP. An economic analysis of patients with active arterial peptic ulcer hemorrhage treated with endoscopic heater probe, injection sclerosis or surgery in a prospective randomised trial. Gastrointestinal Endoscopy 1997;46:105‐12. - PubMed
Gralnek 1998
    1. Gralnek IM, Jensen DM, Gornbein J. Clinical and economic outcomes of individuals with severe peptic ulcer hemorrhage and nonbleeding visible vessel: An analysis of two prospective clinical trials. American Journal of Gastroenterology 1998;93:2047‐56. - PubMed
Green 1978
    1. Green FW, Kaplan MM, Curtis LE. Effect of acid and pepsin on blood coagulation and platelet aggregation: A possible contributor to prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 1978;74(Suppl 1):38‐43. - PubMed
Higgins 2008
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration. Vol. Version 5.0.1 [updated September 2008], Available from www.cochrane‐handbook.org., 2008.
Higham 2002
    1. Higham J, Kang JY, Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects. Gut 2002;50:460‐4. - PMC - PubMed
Jiranek 1996
    1. Jiranek GC, Kozarek RA. A cost effective approach to the patient with peptic ulcer bleeding. Surgery Clinics of North America 1996;76:83‐103. - PubMed
Khuroo 2005
    1. Khuroo MS, Khuroo MS, Farahat KL, Kagevi IE. Treatment with proton pump inhibitors in acute non‐variceal upper gastrointestinal bleeding: a meta‐analysis. Journal of Gastroenterology and Hepatology 2005;20:11‐25. - PubMed
Kolkman 1996
    1. Kolkman JJ, Meuwissen SGM. A review on treatment of bleeding peptic ulcer. A collaborative task of gastroenterologist and surgeon. Scan J Gasteroenterol 1996;31(Suppl 218):16‐25. - PubMed
Laine 1994
    1. Laine L, Peterson WL. Bleeding peptic ulcer. New Eng J Med 1994;331:717‐27. - PubMed
Lau 1998
    1. Lau JY, Chung SCS, Leung JW, Lo KK, Yung Y, Li AKC. The evolution of stigmata of hemorrhage in bleeding peptic ulcers: A sequential endoscopic study. Endoscopy 1998;30(6):513‐518. - PubMed
Lee 1999
    1. Lee JG, Turnipseed S, Romano PS. Endoscopy based triage significantly reduces hospitalisation rates and costs of treating upper GI bleeding: A randomised controlled trial. Gastrointestinal Endoscopy 1999;50:755‐61. - PubMed
Leontiadis 2005
    1. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database of Systematic Reviews 2005, Issue Issue 4. Art. No.: CD002094. [DOI: 10.1002/14651858.CD002094.pub3] - PubMed
Longstreth 1995
    1. Longstreth GF, Feitelberg SP. Outpatient care of selected patients with acute non‐variceal upper gastrointestinal haemorrhage. Lancet 1995;345:108‐11. - PubMed
Longstreth 1997
    1. Longstreth GF. Epidemiology and outcome of patients hospitalized with. American Journal Gastroenterology 1997;92:419‐24. - PubMed
Longstreth 1998
    1. Longstreth GF, Feitelberg SP. Successful outpatient management of acute upper gastrointestinal hemorrhage: use of practice guidelines in a large patient series. Gastrointest Endosc 1998;47:219‐22. - PubMed
Low 1980
    1. Low J, Dodds AJ, Biggs JC. Fibrinolytic activity of gastroduodenal secretions‐a possible role in upper gastrointestinal haemorrhage. Thrombosis Research 1980;17:819‐30. - PubMed
Paimela 2002
    1. Paimela H, Paimela R, Luosujarvi E. Kivilaakso E. Current features of peptic ulcer disease in Finland. Incidence of surgery, hospital admissions and mortality for the disease during the past twenty‐ five years. Scandanavian Journal of Gastroenterology 2002;37:399‐403. - PubMed
Palmer 2002
    1. Palmer. Non‐variceal upper gastrointestinal haemorrhage: guidelines. British Society of Gastroenterology Endoscopy Committee. Gut 2002;51(Suppl 4):1‐6. - PMC - PubMed
Rockall 1995
    1. Rockall TA, Logan RFA, Devlin HB, Northfield TC. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. BMJ 1995;311:222‐6. - PMC - PubMed
Rockall 1996
    1. Rockall TA, Logan RF, Devlin HB, Northfield TC. Selection of patients for early discharge or outpatient care after acute upper gastrointestinal haemorrhage: National Audit of Acute Upper Gastrointestinal Haemorrhage.. Lancet 1996;347:1138‐40. - PubMed
Selby 2000
    1. Selby NM, Kubba AK, Hawkey CJ. Acid suppression in peptic ulcer haemorrhage: a 'meta‐analysis'. Alimentary Pharmacology and Therapeutics 2000;14(9):1119‐26. - PubMed
Silverstein 1981
    1. Silverstein FE, Gilbert DA, Tedesco FJ, Buenger NK, Persing J. The national ASGE survey on upper gastrointestinal bleeding. I. Study design and baseline data.. Gastrointestinal Endoscopy 1981;27(2):73‐9. - PubMed
Spiegel 2003
    1. Spiegel BM, Ofman JJ, Woods K, Vakil NB. Minimizing recurrent peptic ulcer hemorrhage after endoscopic hemostasis: the cost‐effectiveness of competing strategies. American Journal of Gastroenterology 2003;98:86‐97. - PubMed
Sung 2009
    1. Sung JJ, Barkun A, Kuipers EJ, Mössner J, Jensen DM, Stuart R, et al. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Annals of Internal Medicine 2009;150(7):455‐64. - PubMed
van Leerdam 2003
    1. Leerdam ME, Vreeburg EM, Rauws EAJ, Geraedts AM, Tijssen JGP, Reitsma JB, Tytgat GNJ. Acute upper GI bleeding: Did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. American Journal of Gastroenterology 2003;98:1494‐9. - PubMed
Van Rensburg 2003
    1. Rensburg CJ, Hartman M, Thorpe A. Intragastric PH during continuous infusion with pantoprazole in patients with bleeding peptic ulcer. American Journal of Gastroenterology 2003;98:2635‐41. - PubMed
Zandieh 2002
    1. Zandieh I, Andrews C, Brodie M. Prescribing practices and indications for the use of intravenous proton pump inhibitors (IV PPI) in six urban tertiary care centres. Gastrointestinal Endoscopy 2002;55(5):T1883.

References to other published versions of this review

Dorward 2006
    1. Dorward S, Sreedharan A, Leontiadis G, Howden C, Moayyedi P, Forman D. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database of Systematic Reviews 2006, Issue 4:CD005415. - PubMed

MeSH terms